Marinomed Biotech to file for renewed restructuring proceedings without self-administration

Trigger: Failure of the 2024 restructuring plan

The aim of the renewed proceedings is „die finanzielle Stabilität des Unternehmens durch Abschluss eines neuen Sanierungsplans abzusichern". The company emphasizes that „neben weiteren Restrukturierungsmaßnahmen [...] die rechtlichen Möglichkeiten gegenüber Unither Pharmaceuticals aus dem Verkauf des Carragelose-Geschäfts und die Assets der Marinosolv Plattform genutzt werden" should be pursued. In this way, Marinomed is pursuing legal action against the buyer of the Carragelose business in parallel with the restructuring.

Marinomed Biotech AG is listed on the Vienna Stock Exchange on the Official Market under the ticker MARI. In addition, the shares are traded on the open market in Düsseldorf, Frankfurt, Munich, Stuttgart, Tradegate and BSX. The international securities identification number ISIN is ATMARINOMED6, the LEI code is 529900GN3B1EN80XF405, and the WKN is A2N9MM.

Trading and identification of the share

Independently of the current developments, the analysis firm GBC had already issued a „Kaufen" rating for Marinomed Biotech AG on October 28, 2025. That recommendation at the time stands in stark contrast to the company's now-occurred financial difficulties.

The company is headquartered at Hovengasse 25, 2100 Korneuburg, Austria, and can be reached by phone at +43 2262 90300 and by email at office@marinomed.com. The official website is www.marinomed.com. The insider information ended on July 16, 2026, CET/CEST; the announcement was distributed by the EQS Group under news ID 2367244.

Impact on the company and shareholders

With the applied-for restructuring proceedings without self-administration, the company's management will be controlled during the proceedings by a court-appointed restructuring administrator. This model differs from self-administration, in which management largely steers the restructuring itself. For shareholders and creditors, the step means a phase of heightened uncertainty about the continued existence of the company and the value of the shares.

The Marinosolv platform, whose assets are to be brought into the restructuring, forms a second technological pillar of the company alongside Carragelose. What proceeds can be generated from a realization of this platform within the proceedings is currently unclear. The prospects of success of the announced legal steps against Unither Pharmaceuticals likewise cannot be quantified.

From the company's perspective, the renewed filing initiates a new restructuring procedure that is tied to court approval of a revised restructuring plan. How long the proceedings will last and what concrete measures they will include was left open in the announcement. The company merely stated that it would examine „weitere Restrukturierungsmaßnahmen".

The news is likely to have a significant impact on the share price on the Vienna Stock Exchange. The stock is traded under the ticker MARI on the Official Market of the Vienna Stock Exchange as well as on several German exchanges. Investors must prepare for possible price swings and limited trading liquidity until the court decides on the opening of the proceedings.